Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: Results from the PioSwitch Study

Diabetes, Obesity and Metabolism

Volumn 11, Issue 5, 2009, Pages 464-471

  Hohberg, C ^a   Pfützner, Andreas ^b,e   Forst, T ^a   Lubben G ^c   Karagiannis, E ^c   Borchert, M ^a   Schondorf T ^a,d  

^a Institute for Clinical Research and Development   (Germany)

^b ESSLINGEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Takeda Pharma GmbH   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e forum GmbH   (Germany)

Author keywords

Insulin therapy; Pioglitazone; Therapy switch

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

EID: 65449181587     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.00975.x     Document Type: Article

References (36)

1. American Diabetes Association. Clinical practice recommendations 2007. Diabetes Care 2007; 30 (Suppl. 1): S4-S42.
2. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006; 49: 1711-1721.
3. Häring HU, Joost HG, Laube H, et al. Evidenzbasierte Leitlinie -Antihyperglykämische Therapie des Diabetes mellitus Typ 2. in DDG-Guidelines (Eds. Scherbaum WA, Landgraf R). http://www.deutschediabetesgesellschaft.de/redaktion/mitteilungen/ leitlinien/EBL_Dm_Typ2_2003.pdf
4. Calles E, Scandon J, Cipolla M. Diabetes and endothelial dysfunction: A clinical perspective. Endocr Rev 2001; 22: 36-52.
5. Steinberg HO, Baron AD, Steinberg H, et al. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-634.
6. Bressler P, Bailey SR, Matsuda M, DeFronzo RA. Insulin resistance and coronary artery disease. Diabetologia 1996; 39: 1345-1350.
7. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
8. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007; 147: 149-155.
9. Gaede P, LundAndersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
10. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-1817.
11. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
12. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
13. Erdmann E, Charbonnel B, Wilcox RG, et al. PROactive investigators: pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: Data from the PROactive study (PROactive 08). Diabetes Care 2007; 30: 2773-2778.
14. Pfützner A, Forst T. Pioglitazone -an antidiabetic drug with the potential to reduce cardiovascular mortality. Expert Opin Pharmacother 2006; 7: 463-476.
15. Madsbad S, Krarup T, McNair P, et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153-156.
16. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
17. Welch S, Gebhart SS, Bergman RN, Phillips LS. Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 1990; 71: 1508-1518.
18. Forst T, Standl E, Hohberg C, et al. IRISII Study: The IRISII score - assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes. Diabet Med 2004; 21: 1149-1153.
19. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
20. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10 year follow up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002; 105: 310-315.
21. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: A model for the risk of coronary heart disease in type 2 diabetes. Clin Sci 2002; 101: 671-679 [Corrections]. Clin Sci 2002; 102: 679.
22. YkiJarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
23. Schöndorf T, Maiworm A, Emerson N, Forst T, Pfützner A. The role of adiponectin as marker for insulin resistance and cardiovascular risk. Clin Lab 2005; 51: 489-494.
24. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: Action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 1321.
25. Pfützner A, Hohberg C, Lübben G, et al. Pioneer study: PPARγ activation results in an overall improvement of clinical and metabolic markers associated with insulin resistance independent from long term glucose control. Horm Metab Res 2005; 37: 510-515.
26. Jiang G, Zhang BB. Modulation of insulin signaling by insulin sensitizers. Biochem Soc Trans 2005; 33: 358-361.
27. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 278-491.
28. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
29. Langenfeld M, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intimamedia thickness independent of glycemic control in patients with type 2 diabetes mellitus. Circulation 2005; 111: 2525-2531.
30. Forst T, Lübben G, Hohberg C, et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005; 12: 543-550.
31. Pfützner A, Marx N, Lübben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control results from the Pioneer Study. J Am Coll Cardiol 2005; 45: 1925-1931.
32. Hanefeld M, Marx N, Pfützner A, et al. Antiinflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C reactive protein. J Am Coll Cardiol 2007; 49: 290-297.
33. Forst T, Karagiannis E, Lübben G, et al. Pleiotrophic and antiinflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2008; 197: 311-317.
34. Pfützner A, Kunt T, Mondok A, et al. Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004; 27: 682-687.
35. Pfützner A, Schöndorf T, Seidel D, et al. Impact of rosiglitazone on ßcell function, insulin resistance and adiponektin concentrations -results from a double blind oral combination study with glimepiride. Metabolism 2006; 55: 20-25.
36. Schöndorf T, Forst T, Hohberg C, et al. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diabetes Obes Metab 2007; 9: 132-133.